International consensus on use of continuous glucose monitoring

Diabetes Care

Volumn 40, Issue 12, 2017, Pages 1631-1640

  Danne, Thomas ^a   Nimri, Revital ^b   Battelino, Tadej ^c   Bergenstal, Richard M ^d   Close, Kelly L ^e   DeVries, J Hans ^f   Garg, Satish ^g   Heinemann, Lutz ^h   Hirsch, Irl ⁱ   Amiel, Stephanie A ^j   Beck, Roy ^k   Bosi, Emanuele ^l   Buckingham, Bruce ^m   Cobelli, Claudio ⁿ   Dassau, Eyal ^o   Doyle, Francis J ^o   Heller, Simon ^p   Hovorka, Roman ^q   Jia, Weiping ^r   Jones, Tim ^s   Kordonouri, Olga ^a   Kovatchev, Boris ^t   Kowalski, Aaron ^u   Laffel, Lori ^v   Maahs, David ^m   Murphy, Helen R ^w   Nørgaard, Kirsten ^x   Parkin, Christopher G ^y   Renard, Eric ^z   Saboo, Banshi ^aa   Scharf, Mauro ^ab   Tamborlane, William V ^ac   Weinzimer, Stuart A ^ac   Phillip, Moshe ^b   more..

^a Department of Neuropediatrics   (Germany)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^d INTERNATIONAL DIABETES CENTER   (United States)

^e Close Concerns Inc   (United States)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g UNIVERSITY OF COLORADO   (United States)

^h Science and Co   (Germany)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k JAEB CENTER FOR HEALTH RESEARCH   (United States)

^l VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^m STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF PADOVA   (Italy)

^o HARVARD UNIVERSITY   (United States)

^p UNIVERSITY OF SHEFFIELD   (United Kingdom)

^q UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^r SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^s UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^t UNIVERSITY OF VIRGINIA   (United States)

^u JDRF   (United States)

^v HARVARD MEDICAL SCHOOL   (United States)

^w UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^x HVIDOVRE HOSPITAL   (Denmark)

^y CGParkin Communications Inc   (United States)

^z MONTPELLIER UNIVERSITY HOSPITAL   (France)

^aa Diacare and Research Centre   (India)

^ab HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^ac YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CONSENSUS DEVELOPMENT; CONTINUOUS GLUCOSE MONITORING; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERMITTENTLY VIEWED CONTINUOUS GLUCOSE MONITORING; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REAL TIME CONTINUOUS GLUCOSE MONITORING; RISK FACTOR; SELF MONITORING; BLOOD; CLINICAL TRIAL (TOPIC); CONSENSUS; HYPERGLYCEMIA; INTERNATIONAL COOPERATION; METABOLISM; PERSONNEL; PHYSICIAN; STANDARD; STANDARDS;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CLINICAL TRIALS AS TOPIC; CONSENSUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTERNATIONAL AGENCIES; PHYSICIANS; REFERENCE STANDARDS; RESEARCH PERSONNEL;

EID: 85036620716     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1600     Document Type: Article

References (83)

1. Kato N, Cui J, Kato M. Structured self-monitoring of blood glucose reduces glycated hemoglobin in insulin-treated diabetes. J Diabetes Investig 2013; 4:450-453
2. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011;34:262-26
3. Franciosi M, Lucisano G, Pellegrini F, et al.; ROSES Study Group. ROSES: role of self-monitoring of blood glucose and intensive education in patients with type 2 diabetes not receiving insulin. A pilot randomized clinical trial. Diabet Med 2011;28:789-796
4. Kempf K, Kruse J, Martin S. ROSSO-in-praxi follow-up: long-term effects of self-monitoring of blood glucose on weight, hemoglobin A1c, and quality of life in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012;14:59-64
5. Bolli GB. Hypoglycaemia unawareness. Diabetes Metab 1997;23(Suppl. 3):29-35
6. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703
7. American Diabetes Association. Standards of Medical Care in Diabetesd 2017. Diabetes Care 2017;40(Suppl. 1):S1-S135
8. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl JMed 2008;359: 1577-1589
10. Garber AJ, Abrahamson MJ, Barzilay JI, et al.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetesmanagement algorithm- 2016 Executive Summary. Endocr Pract 2016;22:84-113
11. National Institute for Health and Care Excellence (NICE). Diabetes (type 1 and type 2) in children and young people: diagnosis and management, 2015. NICE guideline [NG18]. London, U.K., National Institute for Health and Care Excellence. Available fromwww.nice.org.uk/guidance/NG18. Accessed 4 May 2017
12. National Institute of Diabetes and Digestive and Kidney Diseases. Sickle cell trait & other hemoglobinopathies & diabetes (for providers) [Internet], 2014. Available from http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/index.aspx. Accessed 26 August 2017
13. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47:153-163
14. Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, noniron-deficiency anemia and HbA1c among adults in the US. J Diabetes 2011;3:67-73
15. 1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004;27:1200-1201
16. Bergenstal RM, Gal RL, Connor CG, et al.; T1D Exchange Racial Differences Study Group. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med 2017;167:95-102
17. Shipman KE, Jawad M, Sullivan KM, Ford C, Gama R. Ethnic/racial determinants of glycemic markers in a UK sample. Acta Diabetol 2015;52: 687-692
18. Wolffenbuttel BHR, Herman WH, Gross JL, Dharmalingam M, Jiang HH, Hardin DS. Ethnic differences in glycemicmarkers in patientswith type 2 diabetes. Diabetes Care 2013;36:2931-2936
19. 1c? Yes, to not consider can do great harm! Diabetes Care 2016;39:1458-1461
20. Beck RW, Connor CG, Mullen DM, Wesley, DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017;40:994-999
21. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014;14:CD009122
22. Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
23. 1c levels in T1D Exchange clinic registry participants. Diabetes Care 2013;36:2009-2014
24. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263
25. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for themanagement of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2016;8:55-73
26. Kropff J, Choudhary P, Neupane S, et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care 2017;40:63-68
27. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care 2010; 33:17-22
28. 1c in suboptimally controlled type 1 diabetes; a randomized controlled trial. Diabet Med 2011; 28:1158-1167
29. Battelino T, Conget I, Olsen B, et al.; SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155-3162
30. New JP, Ajjan R, Pfeiffer AF, Freckmann G. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med 2015;32:609-617
31. Wong JC, Foster NC, Maahs DM, et al.; T1D Exchange Clinic Network. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care 2014;37:2702-2709
32. Riveline JP, Schaepelynck P, Chaillous L, et al.; EVADIAC Sensor Study Group. Assessment of patient-led or physician-driven continuous glucose monitoring in patientswith poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care 2012;35:965-971
33. Rachmiel M, Landau Z, Boaz M, et al. The use of continuous glucose monitoring systems in a pediatric population with type 1 diabetes mellitus in real-life settings: the A We SoMe Study Group experience. Acta Diabetol 2015;52:323-329
34. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232
35. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-3419
36. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011;343:d3805
37. Garg SK, Voelmle MK, Beatson CR, et al. Use of continuous glucose monitoring in subjectswith type 1 diabetes onmultiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care 2011;34:574-579
38. Beck RW, Riddlesworth T, Ruedy K, et al.; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017; 317:371-378
39. Huang ES, O'Grady M, Basu A, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care 2010;33:1269-1274
40. McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc 2011;9:13
41. Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. Diabet Med 2015;32: 618-626
42. Ly TT, Brnabic AJ, Eggleston A, et al. A costeffectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014;17:561-569
43. Roze S, Smith-Palmer J, Valentine WJ, et al. Long-term health economic benefits of sensoraugmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. J Med Econ 2016;19:236-242
44. Roze S, Smith-Palmer J, Valentine W, et al. Cost-effectiveness of sensor-augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France. Diabetes Technol Ther 2016;18:75-84
45. Beck RW, Riddlesworth TD, Ruedy K, et al.; DIAMOND Study Group. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374
46. Yoo HJ, An HG, Park SY, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2008;82: 73-79
47. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short-and long-termeffects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012; 35:32-38
48. Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther 2017;19(Suppl. 2):S4-S11
49. Obermaier K, Schmelzeisen-Redeker G, Schoemaker M, et al. Performance evaluations of continuous glucose monitoring systems: precision absolute relative deviation is part of the assessment. J Diabetes Sci Technol 2013;7:824-832
50. Kovatchev BP, Patek SD, Ortiz EA, Breton MD. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol Ther 2015;17:177-186
51. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176
52. Campbell MS, Schatz DA, Chen V, et al.; T1D Exchange Clinic Network. A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. Pediatr Diabetes 2014;15:110-117
53. 1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 2013;36:3535-3542
54. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991;40:223-226
55. Davis MR, Mellman M, Shamoon H. Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM. Diabetes 1992;41:1335-1340
56. Davis SN, Mann S, Galassetti P, et al. Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes 2000; 49:1897-1903
57. Öz G, Kumar A, Rao JP, et al. Human brain glycogen metabolismduring and after hypoglycemia. Diabetes 2009;58:1978-1985
58. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21:1870-1875
59. Fabris C, Patek SD, Breton MD. Are risk indices derived from CGM interchangeable with SMBG-based indices? J Diabetes Sci Technol 2015;10:50-59
60. 1c level. Diabetes Care 2000;23:1830-1834
61. Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation 2001;103:346-347
62. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-219
63. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295: 1681-1687
64. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetesmellitus can be predicted fromself-monitoring blood glucose data. J Clin Endocrinol Metab 1994;79:1659-1662
65. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes 2013;62:1405-1408
66. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 2015;38:1610-1614
67. Service FJ. Glucose variability. Diabetes 2013; 62:1398-1404
68. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 2015;38:1615-162
69. Rodbard D. Thechallenges ofmeasuringglycemic variability. J Diabetes Sci Technol 2012;6:712-715
70. Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 2016;39:502-510
71. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994;43:313-317
72. Kovatchev BP, Flacke F, Sieber J, Breton MD. Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine selfmonitored blood glucose data. Diabetes Technol Ther 2014;16:303-309
73. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006;105:244-252
74. Eslami S, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucose variability measures and their effect on mortality: a systematic review. Intensive Care Med 2011;37:583-593
75. Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther 2012;14:1008-1012
76. El-Laboudi AH, Godsland IF, Johnston DG, Oliver NS. Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. Diabetes Technol Ther 2016;18:806-812
77. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 2017;40:832-838
78. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl. 1):S55-S67
79. International Diabetes Center. AGP - Ambulatory Glucose Profile: AGP reports. Available from http://www.agpreport.org/agp/agpreports. Accessed 17 July 2017
80. Medtronic. New CareLink iPro Pattern Snapshot. Available from https://professional. medtronicdiabetes.com/para/new-carelink-ipro-pattern-snapshot-report. Accessed 29 August 2017
81. Dexcom. DexcomCLARITY Diabetes Management Software. Available from https://www.dexcom.com/clarity. Accessed 29 August 2017
82. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15:198-211
83. Xing D, Kollman C, Beck RW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358